Dispatch of Scheme Booklet to Shareholders

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) (Sirtex) today announces the dispatch of the scheme booklet (Scheme Booklet) and personalised proxy forms to shareholders in relation to the proposed acquisition of all of the shares in Sirtex by Grand Pharma Sphere (Australia Bidco) Pty Ltd, an entity owned by CDH Genetech Limited and China Grand Pharmaceutical and Healthcare Holdings Limited (collectively, the Bidders) by way of scheme of arrangement (Scheme). Shareholders who have elected to receive communications electronically have been sent an email with links to where they can download the Scheme Booklet and proxy form while other shareholders have been mailed a printed copy of the Scheme Booklet.

A copy of the Scheme Booklet was lodged with the ASX on 1 August 2018 and is available on Sirtex’s website at www.sirtex.com.

All Sirtex shareholders are encouraged to read the Scheme Booklet in its entirety before deciding whether or not to vote in favour of the Scheme. Shareholders can vote either by attending the scheme meeting (Scheme Meeting) in person, or by lodging a proxy form with the Sirtex share registry by 10:00am (Sydney time) on Saturday, 8 September 2018. Any proxy forms received after that time will not be valid for the scheduled Scheme Meeting. Details of how to lodge the proxy form are included in the Scheme Booklet.

The Scheme Meeting will be held at 10:00am (Sydney time) on Monday, 10 September 2018 at the Royal Automobile Club of Australia, 89 Macquarie Street, Sydney NSW 2000.

If shareholders approve the Scheme at the Scheme Meeting and it is subsequently approved by the Federal Court of Australia, the Scheme will be implemented on the implementation date, which is expected to be on 20 September 2018.

If after reading the Scheme Booklet you have any further questions in relation to the Scheme or the Scheme Booklet, please contact the Sirtex Shareholder Scheme Information Line on 1300 794 682 (within Australia) or +61 1300 794 682 (outside Australia) on Monday to Friday between 8:30am and 5:30pm (Sydney time) or consult your legal, financial, taxation or other professional adviser.

– ENDS –

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with over 86,000 doses supplied and administered at over 1,160 medical centres in more than 40 countries.
Investor Enquiries:

Mr Andrew McLean
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Head of Investor Relations &
Corporate Development
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:
http://www.sirtex.com/au/investors/email-alerts/

Follow us on Twitter: @sirtexmedical
Visit us on LinkedIn: Sirtex Medical Limited